Q linea AB

Chart & Performance

D1W1MN

P/E

—

P/S

9.66

EPS

—

Div Yield, %

—

Shrs. gr., 5y

-23.43%

Rev. gr., 5y

114.75%

Revenues

11m

+369.86%

Net income

-182m

L-15.86%

CFO

-162m

L-11.17%

Earnings

Jul 10, 2026

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Q-linea AB (publ), founded in 2008 and based in Uppsala, Sweden, specializes in developing diagnostic instruments and associated consumables for infection detection. The company crafts advanced in vitro diagnostic platforms, specifically engineered to identify infectious diseases. A key product is ASTar, an innovative system designed to rapidly assess antibiotic susceptibility in positive blood cultures. Q-linea's overarching mission is to deliver cutting-edge solutions to healthcare professionals.

URL

https://www.qlinea.com/

IPO date

Dec 07, 2018

Employees

149

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT